Mucocutaneous leishmaniasis in a 10-year-old female patient from the ecuadorian amazon. Case report [Version 1; Peer Review - In process]
DOI:
https://doi.org/10.56294/saludcyt2023249Keywords:
Leishmaniasis, Ulcer, Vector, Sandfly, MeglumineAbstract
Leishmaniasis comprises a set of clinical syndromes caused by protozoa of the genus Leishmania. The infection can be located in the skin and/or subcutaneous tissue with or without regional adenopathy (cutaneous leishmaniasis), in the oro-nasal mucosa (mucocutaneous leishmaniasis) or generally affect the phagocytic mononuclear system (visceral leishmaniasis). 400 000 new cases of human leishmaniasis in Asia, Africa, countries of the Mediterranean basin, the Near East and America. Each Leishmania species has a specific geographic distribution and causes characteristic clinical syndromes. This case report presents a 10-year-old patient with painful ulcerative lesions located in the oral region and whitish plaques on the tongue that prevent food intake. Receive treatment for the patient's clinic using Meglumine Antimonate with a favorable prognosis
References
1. García-Almagro D. Leishmaniasis cutánea. Actas Dermosifiliogr 2005; 96(1):1-24. https://doi.org/10.1016/S0001-7310(05)73027-1
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PloS one 2012; 7(5), e35671. https://doi.org/10.1371/journal.pone.0035671
3. Hashiguchi Y, Gomez L. EA, Cáceres AG, Velez LN,Villegas NV, Hashiguchi K, et al. Andean cutaneous leishmaniasis (Andean-CL, uta) in Peru and Ecuador: the vector Lutzomyia sand flies and reservoir mammals. Acta Tropica 2018; 178:264-75. https://doi.org/10.1016/j.actatropica.2017.12.008
4. Gomez EA, Kato H, Mimori T, Hashiguchi Y. Distribution of Lutzomyia ayacuchensis, the vector of Andean-type cutaneous leishmaniasis, at different altitudes on the Andean slope of Ecuador. Acta Tropica 2014; 137:118-22. https://doi.org/10.1016/j.actatropica.2014.05.006
5. Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. The Lancet Infectious Diseases 2007; 7(9):581-96. https://doi.org/10.1016/S1473-3099(07)70209-8
6. WHO. The world health report 2004. Changing history. Geneva: WHO, 2004.
7. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561–77. https://doi.org/10.1016/S0140-6736(05)67629-5
8. Marco JD, Barroso PA, Mimori T, Locatelli FM, Tomatani A, Mora MC, Cajal SP, Nasser JR, Parada LA, Taniguchi T, et al. Polymorphism-specific PCR enhances the diagnostic performance of American tegumentary leishmaniasis and allows the rapid identification of Leishmania species from Argentina. BMC Infect. Dis 2012; 12:191. https://doi.org/10.1186/1471-2334-12-191
9. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management. J. Am. Acad. Dermatol 2015; 73(6):911-26. https://doi.org/10.1016/j.jaad.2014.08.051
10. García Bustos MF, Barrio A, Parodi Ramoneda CM, Beckar J, Moreno S, Basombrío MAM. Miltefosina versus antimoniato de meglumina en el tratamiento de la leishmaniasis mucosa. Acta Tropica 2014, 74(5):371-7. https://doi.org/10.1016/j.actatropica.2015.11.008
Published
Issue
Section
License
Copyright (c) 2023 Miguel David Alvarez Saltos , Andrés Eduardo Alvarado Quezada, Sandy Giselle Nina Inca, Yoselyn Isabel Choez Abendaño (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
